Ultragenyx Pharmaceutical
RARE
#3686
Rank
โ‚น315.46 B
Marketcap
โ‚น3,270
Share price
0.08%
Change (1 day)
-17.80%
Change (1 year)

Earnings for Ultragenyx Pharmaceutical (RARE)

Earnings in 2025 (TTM): -โ‚น44.95 Billion

According to Ultragenyx Pharmaceutical's latest financial reports the company's current earnings are โ‚น0.63 Billion. In 2024 the company made an earning of -โ‚น45.54 Billion, an increase over its 2023 earnings that were of -โ‚น48.96 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Ultragenyx Pharmaceutical from 2013 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -โ‚น44.95 Billion-1.29%
2024 -โ‚น45.54 Billion-6.99%
2023 -โ‚น48.96 Billion-17.65%
2022 -โ‚น59.46 Billion55.52%
2021 -โ‚น38.23 Billion178.53%
2020 -โ‚น13.73 Billion-59.64%
2019 -โ‚น34.01 Billion1.46%
2018 -โ‚น33.52 Billion12.9%
2017 -โ‚น29.69 Billion32.63%
2016 -โ‚น22.39 Billion67.87%
2015 -โ‚น13.34 Billion160.2%
2014 -โ‚น5.13 Billion66.64%
2013 -โ‚น3.08 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
BioMarin Pharmaceutical
BMRN
โ‚น61.30 B-230.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
โ‚น0.44 B-100.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Esperion Therapeutics
ESPR
-โ‚น2.48 Billion-94.71%๐Ÿ‡บ๐Ÿ‡ธ USA
Lexicon Pharmaceuticals
LXRX
-โ‚น6.19 Billion-86.78%๐Ÿ‡บ๐Ÿ‡ธ USA